|
시장보고서
상품코드
2038681
셀리악병 치료 시장 : 시장 비즈니스 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)Celiac Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035 |
||||||
세계의 셀리악병 치료 시장은 2025년에 7억 1,260만 달러로 평가되었고, 2035년까지 연평균 복합 성장률(CAGR) 10.8%로 성장할 전망이며, 20억 달러에 이를 것으로 예측됩니다.
셀리악병 치료 산업은 체강 질병의 유병률 증가와 첨단 진단 솔루션에 대한 의료진의 인식이 높아짐에 따라 강력한 성장세를 보이고 있습니다. 검출률이 높아짐에 따라 효과적인 치료법에 대한 수요도 지속적으로 증가하여 전체 시장 확대를 뒷받침하고 있습니다. 지속적인 연구 개발 노력은 의약품 치료의 혁신을 주도하고 있으며, 시장 진입이 예상되는 잠재적 치료제의 파이프라인을 확장하는 데 기여하고 있습니다. 동시에 글루텐 프리 식단의 보급과 비침습적 진단 방법의 발전으로 질병 관리가 개선되고 더 빠른 진단이 가능해졌습니다. 소화기 질환에 특화된 전문 의료시설의 확대와 치료 서비스 접근성 향상으로 환자들의 진료율은 더욱 높아지고 있습니다. 첨단 치료법을 대상으로 한 임상시험에 대한 투자 증가와 더불어 장기 관리를 위한 지지요법 제품의 보급으로 치료 순응도가 향상되고 있습니다. 의료비 증가와 의료용 영양 제품 및 처방 요법의 유통망 개선도 전체 시장의 지속적인 성장을 견인하는 데 중요한 역할을 하고 있습니다.
| 시장 범위 | |
|---|---|
| 개시 연도 | 2025년 |
| 예측 기간 | 2026-2035년 |
| 개시 시점 시장 규모 | 7억 1,260만 달러 |
| 예측 시장 규모 | 20억 달러 |
| CAGR | 10.8% |
비타민 및 미네랄 보충제 시장은 2025년에 3억 4,540만 달러에 달했으며, 2035년에는 9억 5,070만 달러로 확대될 것으로 예측됩니다. 이 시장은 질병으로 인한 영양 결핍을 관리하는 데 있어 건강기능식품의 중요한 역할로 인해 확고한 입지를 구축하고 있습니다. 환자들은 회복을 돕고 전반적인 건강을 유지하기 위해, 특히 영양소 흡수와 관련된 문제를 해결하기 위해 이러한 보충제에 의존하는 경우가 많습니다. 식이 제한이 있는 개인을 위한 전문 영양 제품에 대한 수요 증가도 이 부문의 성장에 기여하고 있습니다. 이러한 솔루션은 소화기 건강과 장기적인 질병 관리를 지원하기 때문입니다.
경구 부문은 2025년 63.3%의 점유율을 차지했으며, 2035년까지 연평균 10.7%의 성장률을 보일 것으로 전망됩니다. 경구용 치료는 편의성과 투여의 용이성으로 인해 널리 선호되고 있으며, 환자는 임상적 도움 없이도 스스로 치료를 관리할 수 있습니다. 혁신적인 경구용 제제에 대한 규제 당국의 지원과 지속적인 연구 개발 활동이 결합되어 보다 효과적이고 접근하기 쉬운 치료 옵션이 도입되고 있으며, 이는 이 부문의 성장을 주도하고 있습니다.
북미의 셀리악병 치료 시장은 2025년에 44.2%의 점유율을 차지했으며, 2035년까지 연평균 복합 성장률(CAGR) 10.6%를 나타낼 것으로 예측됩니다. 이 지역의 성장은 잘 구축된 헬스케어 인프라와 자가면역질환 연구에 종사하는 제약사들의 강력한 존재감이 뒷받침하고 있습니다. 첨단 치료법의 높은 보급률, 유리한 상환 정책, 혁신적인 치료법을 위한 임상 개발에 대한 관심이 높아지면서 이 지역 전체에서 시장 확대가 더욱 가속화되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법
제2장 주요 요약
제3장 업계 인사이트
제4장 경쟁 구도
제5장 시장 추산 및 예측 : 치료법별(2022-2035년)
제6장 시장 추산 및 예측 : 투여 경로별(2022-2035년)
제7장 시장 추산 및 예측 : 최종 용도별(2022-2035년)
제8장 시장 추산 및 예측 : 지역별(2022-2035년)
제9장 기업 개요
AJY 26.06.11The Global Celiac Disease Treatment Market was valued at USD 712.6 million in 2025 and is estimated to grow at a CAGR of 10.8% to reach USD 2 billion by 2035.
The celiac disease treatment industry is experiencing strong growth due to the rising prevalence of the condition and improved awareness among healthcare professionals regarding advanced diagnostic solutions. As detection rates increase, the demand for effective treatment options continues to rise, supporting overall market expansion. Ongoing research and development efforts are driving innovation in pharmaceutical therapies, contributing to a broader pipeline of potential treatments expected to enter the market. At the same time, the growing adoption of gluten-free dietary practices and advancements in non-invasive diagnostic methods are improving disease management and enabling quicker diagnosis. Expansion of specialized healthcare facilities focused on gastrointestinal disorders, along with better access to treatment services, is further strengthening patient adoption rates. Increasing investments in clinical trials targeting advanced therapeutic approaches, along with the availability of supportive care products for long-term management, are enhancing treatment adherence. Rising healthcare spending and improved distribution networks for medical nutrition and prescription therapies are also playing a key role in driving sustained growth across the market.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $712.6 Million |
| Forecast Value | $2 Billion |
| CAGR | 10.8% |
The vitamins and minerals supplements segment reached USD 345.4 million in 2025 and is projected to increase to USD 950.7 million by 2035. This segment holds a strong position due to the essential role of nutritional supplementation in managing deficiencies associated with the condition. Patients often rely on these supplements to support recovery and maintain overall health, particularly in addressing nutrient absorption challenges. Growing demand for specialized nutritional products tailored to individuals with dietary restrictions is further contributing to segment growth, as these solutions support digestive health and long-term disease management.
The oral segment accounted for 63.3% share in 2025 and is expected to grow at a CAGR of 10.7% throughout 2035. Oral therapies are widely preferred due to their convenience and ease of administration, allowing patients to manage treatment independently without requiring clinical assistance. Regulatory support for innovative oral formulations, combined with continuous research and development activities, is leading to the introduction of more effective and accessible treatment options, which are driving segment expansion.
North America Celiac Disease Treatment Market held a 44.2% share in 2025 and is anticipated to grow at a CAGR of 10.6% through 2035. The region's growth is supported by a well-established healthcare infrastructure and a strong presence of pharmaceutical companies engaged in autoimmune disease research. High adoption of advanced therapies, favorable reimbursement policies, and increasing focus on clinical development for innovative treatments are further accelerating market expansion across the region.
Key companies operating in the Global Celiac Disease Treatment Market include Amgen, Takeda Pharmaceutical Company, ActoBio, Novartis, Teva Pharmaceutical, Viatris, Amneal Pharmaceuticals, BioLineRx, Calypso Biotech, Hikma Pharmaceuticals, Glenmark Life Sciences, Zydus Pharmaceuticals, Innovate Biopharmaceutical, and General Mills. Companies in the Celiac Disease Treatment Market are focusing on strengthening their market position through continuous innovation and strategic initiatives. Significant investments are being made in research and development to advance targeted therapies and improve treatment effectiveness. Organizations are actively pursuing collaborations, partnerships, and licensing agreements to accelerate product development and expand their therapeutic portfolios. Increasing focus on clinical trials is enabling the introduction of novel treatment options with improved efficacy and safety profiles. Companies are also enhancing their distribution networks and expanding into emerging markets to capture new growth opportunities.
Table of Contents
Chapter 1 Research methodology
- 1.1 Market scope and definition
- 1.2 Research approach
- 1.3 Quality commitments
- 1.3.1 GMI AI policy and data integrity commitment
- 1.3.1.1 Source consistency protocol
- 1.3.1 GMI AI policy and data integrity commitment
- 1.4 Research trail and confidence scoring
- 1.4.1 Research trail components
- 1.4.2 Scoring components
- 1.5 Data collection
- 1.5.1 Partial list of primary sources
- 1.6 Data mining sources
- 1.6.1 Paid sources
- 1.6.1.1 Sources, by region
- 1.6.1 Paid sources
- 1.7 Base estimates and calculations
- 1.7.1 Revenue share analysis
- 1.7.2 Base year calculation
- 1.8 Forecast model
- 1.9 Research transparency addendum
- 1.9.1 Source attribution framework
- 1.9.2 Quality assurance metrics
- 1.9.3 Our commitment to trust
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
- 2.2 Key market trends
- 2.2.1 Business trends
- 2.2.2 Regional trends
- 2.2.3 Treatment trends
- 2.2.4 Route of administration trends
- 2.2.5 End use trends
- 2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of celiac disease
- 3.2.1.2 Technological advancements in therapeutic options
- 3.2.1.3 Increasing demand for gluten-free products
- 3.2.1.4 Increasing diagnostic technologies for celiac disease diagnosis
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of gluten-free products
- 3.2.2.2 Stringent regulatory approvals
- 3.2.3 Market opportunities
- 3.2.3.1 Development of novel immunotherapies
- 3.2.3.2 Increasing adoption of nutraceutical and supplement innovation
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape (Driven by Primary Research)
- 3.4.1 North America
- 3.4.1.1 U.S.
- 3.4.1.2 Canada
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.1 North America
- 3.5 Pipeline analysis (Driven by Primary Research)
- 3.6 Future market analysis (Driven by Primary Research)
- 3.7 Investment and funding landscape
- 3.8 Impact of AI/ Gen AI on the market (Driven by Primary Research)
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 North America
- 4.2.2 Europe
- 4.2.3 Asia Pacific
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Treatment, 2022 - 2035 ($ Mn)
- 5.1 Key trends
- 5.2 Vitamins and mineral supplements
- 5.3 Gluten-free diet
- 5.4 Medical therapies
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Specialty clinics
- 7.4 Homecare settings
- 7.5 Other end users
Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 ActoBio
- 9.2 Amgen
- 9.3 Amneal Pharmaceuticals
- 9.4 BioLineRx
- 9.5 Calypso Biotech
- 9.6 General Mills
- 9.7 Glenmark Life Sciences
- 9.8 Hikma Pharmaceuticals
- 9.9 Innovate Biopharmaceutical
- 9.10 Novartis
- 9.11 Takeda Pharmaceutical Company
- 9.12 Teva Pharmaceutical
- 9.13 Viatris
- 9.14 Zydus Pharmaceuticals
